Trial Profile

Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Astrocytoma; Glioma; Oligodendroglioma
Focus Therapeutic Use

Most Recent Events

02 Apr 2025 Planned End Date changed from 27 Feb 2026 to 30 Nov 2026.
02 Apr 2025 Status changed from recruiting to active, no longer recruiting.
07 Aug 2023 Planned number of patients changed from 95 to 70.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com